3Degrees Strengthens European Biomethane Solutions with ISCC EU Certification
OSLO, Norway--(BUSINESS WIRE)--3Degrees, a leading global climate solutions provider, has further reinforced its commitment to decarbonisation in the European markets by securing ISCC EU certification for its biomethane solutions. This certification enables 3Degrees to offer clients ISCC EU-certified biomethane certificates, providing robust assurance and traceability for their renewable energy strategies.
3Degrees Strengthens European Biomethane Solutions with ISCC EU Certification
Share
The ISCC EU certification, awarded by the International Sustainability and Carbon Certification (ISCC) system, is recognised as a premier standard for demonstrating compliance with the European Union's rigorous sustainability requirements. With this certification, 3Degrees continues to support organisations in meeting both voluntary and compliance decarbonisation objectives with the highest level of environmental integrity.
'With two decades of experience in the renewable energy and climate sector, 3Degrees has a well-established presence in the market, and this certification underscores our ongoing dedication to enabling organisations to take urgent climate action,' said Zvonko Ikic, Senior Biomethane Originator at 3Degrees. 'Through ISCC EU-certified biomethane solutions, we ensure that our clients' renewable energy procurement is fully aligned with the current and future sustainability standards.'
'This marks a significant milestone in our journey to empower customers that have a carbon footprint in Europe with a comprehensive suite of climate solutions,' said Owain Morgan, President of Markets at 3Degrees. 'Our global biomethane platform is a cornerstone of our climate action strategy, and we are excited about the positive impact this certification will unlock for our clients and the broader transition to a low-carbon future.'
For more information about 3Degrees' biomethane offerings and renewable natural gas (RNG) services, please visit 3Degrees.com.
About 3Degrees
3Degrees is a leading global climate solutions provider, pioneer of environmental markets, and Certified B Corporation with offices across Asia, North America, and Europe. Our work is driven by the need for urgent climate action and has been for nearly 20 years. We deliver a full suite of clean energy and decarbonisation solutions to help global Fortune 500 companies, utilities, and other organizations achieve their climate goals and address emissions in the fight against climate change. The 3Degrees team brings a commitment to integrity and deep expertise in climate strategy and implementation across scopes 1, 2, and 3 emissions, including global environmental commodities, renewable energy and carbon project development, and supply chain decarbonisation. We help develop and deploy impactful climate solutions that make good business sense and advance an equitable transition to a low-carbon future. Learn more at 3Degrees.com or follow us on LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Motor 1
an hour ago
- Motor 1
Lamborghini Pins Hopes on Synthetic Fuel to Save Combustion Engines
It's abundantly clear to Lamborghini that removing the internal combustion engine from the equation will hinder demand. The company has already delayed the launch of its first EV and recently disclosed plans to keep combustion engines for 'as long as possible.' But ICE doesn't necessarily have to run on gasoline. For instance, the new twin-turbo 4.0-liter V8 can feed on synthetic fuel without compromises. In an interview with Australian magazine CarExpert , Lamborghini's Chief Technical Officer argued that synthetic fuel 'could be the savior of the combustion engine.' Rouven Mohr added that the Temerario's new engine can 'deliver optimal efficiency and performance with both solutions [gas and e-fuel].' He also touched on the emotional aspect, claiming that EVs still can't match the excitement of an ICE car. Lamborghini Temerario's V-8 Photo by: Lamborghini 'If you ask me the emotion side at the moment, like I said before, I don't see the [electric] solution that is convincing now. Its time will come, trust me, because this kind of technology transformation needs longer.' But even when enthusiasts warm up to the idea of hot EVs, Mohr believes there will come a time when tomorrow's youngsters will realize that 'okay, the old combustion thing is cool.' Lamborghini is pinning its hopes on synthetic fuel to extend the life of ICEs beyond 2035, when the European Union will ban sales of new cars that produce harmful emissions. The ruling doesn't explicitly outlaw combustion engines, as it leaves room for e-fuels, provided they're carbon neutral. Synthetic fuels have yet to catch on, and even if they do in the coming years, they'll remain expensive until production scales up. That, however, isn't likely to deter Lamborghini buyers. The exotic Italian marque, headquartered in Sant'Agata Bolognese, is part of the Volkswagen Group, which also includes Porsche. That's relevant because Porsche has been producing e-fuel in Chile since late 2022, when it filled a 911 with synthetic fuel made from water and carbon dioxide using wind energy. Porsche fills up 911 with synthetic fuel Porsche claims its electric fuel is 'produced from hydrogen obtained purely from renewable energy and CO₂ (carbon dioxide).' It's being manufactured at an industrial scale in partnership with Chilean operator Highly Innovative Fuels (HIF) to make 'combustion engines as near to net carbon neutral as possible.' While a 911 costs less than half the price of a Temerario , it still starts at $129,950 in base Carrera form. Porsche buyers likely won't mind paying extra for synthetic fuel if it means keeping their combustion engines running. Porsche has vowed that the last car it makes with a combustion engine will be the 911, and that a fully electric version won't arrive this decade. However, a hybrid is already here . Beyond Lamborghini and Porsche, Bentley and Bugatti are also pursuing e-fuels. Outside the Volkswagen Group, Ferrari has also shown interest in synthetic fuel. In the mainstream segment, Toyota, Mazda, and Subaru are collaborating to explore whether ICEs can survive without relying on fossil fuels. Toyota has even gone a step further, experimenting with hydrogen combustion engines . Let's be real. Making e-fuels viable for widespread adoption won't happen overnight, if it happens at all. Large-scale production and distribution will take years and require collective industry effort. With most automakers fully committed to global EV adoption, we're skeptical about whether enough financial resources remain to push synthetic fuels forward. Perhaps they'll become a niche for high-end buyers willing to pay the price, but the majority will have to look elsewhere. Lamborghini Is Doing Better Than Ever: Lamborghini Outsold Bentley in 2024 Lamborghini Had Record Sales in 2024 Get the best news, reviews, columns, and more delivered straight to your inbox, daily. back Sign up For more information, read our Privacy Policy and Terms of Use . Share this Story Facebook X LinkedIn Flipboard Reddit WhatsApp E-Mail Got a tip for us? Email: tips@ Join the conversation ( )
Newsweek
2 hours ago
- Newsweek
Project 2025 Coauthor: Trump Tariffs Could Endanger Health Care
Advocates for ideas and draws conclusions based on the interpretation of facts and data. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. President Donald Trump is right to play hardball on trade with Europe. The European Union targets leading American companies with rules, fines, and other punitive actions that undermine their ability to do business in EU countries and deliver technologies to their citizens and small businesses. However, there are some lines that we should not cross in response to trade tensions—like the tariffs President Trump is expected to impose on imported medicines any day now. The president can levy so-called Section 232 tariffs on imports deemed a threat to national security. While that rationale may apply to medicines from China, imports from Europe and Japan pose no such threat. Tariffs on European and Japanese medicines would harm Americans who rely on prescription drugs. They would disrupt the small firms that underpin our health care system—disproportionately hurting early-stage biotech startups, specialized manufacturers, and independent pharmacies, especially in rural communities. These companies operate lean and are laser-focused. Most emerging biotechs, in fact, revolve around a single drug candidate. They have small teams, tight budgets, and years of regulatory hurdles ahead. Many rely on active pharmaceutical ingredients sourced from Europe to develop their therapies. Tariffs on those imports wouldn't just slow medical progress—they could stop it in its tracks. That's because small firms aren't on the sidelines of drug development. They are the front line. In 2024, nearly two-thirds of all U.S. clinical trials were launched by emerging biopharma companies. Last year, small businesses developed 85 percent of newly approved drugs and brought more than half to market on their own. Breakthroughs require reliable, affordable inputs. A full one-third of the active pharmaceutical ingredients in Americans' medicines come from Europe. Building new U.S. pharmaceutical plants can take up to a decade and cost $2 billion. Waiting that long isn't an option for a startup betting everything on one product. Even established manufacturers aren't immune. Many of America's nearly 1,600 domestic facilities—which produce approximately one-half of U.S. medicines—still depend on European ingredients. Tariffs would spike their costs and strain an already fragile supply chain. Some may be forced to pull workers off the factory floor. WASHINGTON, DC - APRIL 02: U.S. President Donald Trump holds up a chart while speaking during a 'Make America Wealthy Again' trade announcement event in the Rose Garden at the White House on April 2,... WASHINGTON, DC - APRIL 02: U.S. President Donald Trump holds up a chart while speaking during a 'Make America Wealthy Again' trade announcement event in the Rose Garden at the White House on April 2, 2025 in Washington, DC. MoreThen there are the pharmacies. Unlike big chains, independent pharmacies often can't negotiate bulk deals or absorb sudden price hikes. A steep tariff could erase already thin margins, forcing many to shut their doors, including in underserved and rural communities that already lack sufficient access to pharmacies. In 2023 alone, the U.S. imported close to $130 billion in pharmaceutical products from Europe. A tariff, of 25 percent for instance, could translate to tens of billions in new costs for our health care system. Those dollars won't just hit corporate balance sheets. They'll show up in Medicare and Medicaid budgets, insurance premiums, and out-of-pocket costs for seniors and working families. Placing tariffs on medicines is not like taxing handbags or hubcaps. There's often no clear "substitute" for the medicine that works best for a particular patient. If a treatment is made in Ireland or Switzerland, a tariff doesn't create a U.S. version. It creates delay, financial strain, or worse—outright loss of access. Developed countries have long treated medicines as off-limits in trade disputes for one simple reason: patients' lives should never be used as leverage in a trade war. If President Trump's goal is to keep America from relying on adversaries like China for key medicines, life-saving European drugs shouldn't be caught in the crossfire. Entrepreneurs and small business owners are not asking for special favors. They merely want predictability, light government intervention, access to markets, and a fair shot. Drug tariffs will inject turmoil into a sector that needs stability. For biotech startups and other small businesses, these tariffs aren't just a cost increase—they are an existential threat. President Trump is right to confront trade inequities, intellectual property theft, and other countries' lack of compliance with previous trade deals. But when it comes to medicines, tariffs will cause broad-based harm. Practically speaking, tariffs will not build domestic capacity any time soon and they will not protect American innovation. Medicines must remain exempt from tariff actions against allies like Europe and Japan. American patients and the small businesses powering our health care system need this stability and assurance. Karen Kerrigan is president and CEO of the Small Business and Entrepreneurship Council ( in Washington, D.C. She was the author of Project 2025's chapter on the Small Business Administration. The views expressed in this article are the writer's own.
Yahoo
2 hours ago
- Yahoo
HOCHTIEF and IONOS submit EoI for building AI Gigafactory in Europe
HOCHTIEF, in partnership with cloud solutions provider IONOS Group, has expressed interest in constructing and operating an AI 'Gigafactory' in Europe. The expression of interest (EoI), submitted to the European Commission (EC), outlines a project that will initially feature over 50,000 graphics processing units (GPUs), with the potential to scale up to over 100,000 GPUs. These facilities will be fully integrated into European standards, with an aim to improve the region's AI capabilities, a statement from HOCHTIEF said. The proposed high-performance data centre infrastructure, utilising the latest GPU technology, is expected to commence operations by 2027. The EU is stated to have plans to invest €20bn ($23bn) in five AI Gigafactories. The EC will detail the next phases of the selection process in the coming months, as the consortium prepares to refine its plans. HOCHTIEF, engaged in data centre development and construction, offers expertise across planning, financing, construction, operation, and digital infrastructure. The company has implemented around 6GW of projects, focusing on sustainable solutions that optimise the entire life cycle of data centres. IONOS Group, meanwhile, with over three decades of experience in digitalisation and cloud infrastructure operation, provides the technological foundation for the General Data Protection Regulation-compliant operation of scalable AI workloads. The consortium also includes specialised technology, utility, security companies, and research and development institutions. The financing for the project will follow a standard industry structure, using equity, partnership models, and debt financing, complemented by targeted EU funding. Last month, the joint venture of construction and real-estate provider Implenia and HOCHTIEF was awarded a contract for the '733 Tunnel Ostbahnhof', a component of the Munich S-Bahn expansion project by Deutsche Bahn, the German state-owned railway company. "HOCHTIEF and IONOS submit EoI for building AI Gigafactory in Europe" was originally created and published by World Construction Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
